D
David M. Nanus
Researcher at Cornell University
Publications - 368
Citations - 24894
David M. Nanus is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 70, co-authored 335 publications receiving 21709 citations. Previous affiliations of David M. Nanus include Rosalind Franklin University of Medicine and Science & Population Council.
Papers
More filters
Journal ArticleDOI
Integrative clinical genomics of advanced prostate cancer
Dan R. Robinson,Eliezer M. Van Allen,Eliezer M. Van Allen,Yi-Mi Wu,Nikolaus Schultz,Robert J. Lonigro,Juan Miguel Mosquera,Bruce Montgomery,Mary-Ellen Taplin,Colin C. Pritchard,Gerhardt Attard,Gerhardt Attard,Himisha Beltran,Wassim Abida,Robert K. Bradley,Jake Vinson,Xuhong Cao,Pankaj Vats,Lakshmi P. Kunju,Maha Hussain,Felix Y. Feng,Scott A. Tomlins,Kathleen A. Cooney,David Smith,Christine Brennan,Javed Siddiqui,Rohit Mehra,Yu Chen,Yu Chen,Dana E. Rathkopf,Dana E. Rathkopf,Michael J. Morris,Michael J. Morris,Stephen B. Solomon,Jeremy C. Durack,Victor E. Reuter,Anuradha Gopalan,Jianjiong Gao,Massimo Loda,Rosina T. Lis,Michaela Bowden,Michaela Bowden,Stephen P. Balk,Glenn C. Gaviola,Carrie Sougnez,Manaswi Gupta,Evan Y. Yu,Elahe A. Mostaghel,Heather H. Cheng,Hyojeong Mulcahy,Lawrence D. True,Stephen R. Plymate,Heidi Dvinge,Roberta Ferraldeschi,Roberta Ferraldeschi,Penny Flohr,Penny Flohr,Susana Miranda,Susana Miranda,Zafeiris Zafeiriou,Zafeiris Zafeiriou,Nina Tunariu,Nina Tunariu,Joaquin Mateo,Joaquin Mateo,Raquel Perez-Lopez,Raquel Perez-Lopez,Francesca Demichelis,Francesca Demichelis,Brian D. Robinson,Marc H. Schiffman,David M. Nanus,Scott T. Tagawa,Alexandros Sigaras,Kenneth Eng,Olivier Elemento,Andrea Sboner,Elisabeth I. Heath,Howard I. Scher,Howard I. Scher,Kenneth J. Pienta,Philip W. Kantoff,Johann S. de Bono,Johann S. de Bono,Mark A. Rubin,Peter S. Nelson,Levi A. Garraway,Levi A. Garraway,Charles L. Sawyers,Arul M. Chinnaiyan +89 more
TL;DR: This cohort study provides clinically actionable information that could impact treatment decisions for affected individuals and identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF.
Journal ArticleDOI
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran,Himisha Beltran,Davide Prandi,Juan Miguel Mosquera,Juan Miguel Mosquera,Matteo Benelli,Loredana Puca,Joanna Cyrta,Clarisse Marotz,Eugenia G. Giannopoulou,Balabhadrapatruni V. S. K. Chakravarthi,Sooryanarayana Varambally,Scott A. Tomlins,David M. Nanus,Scott T. Tagawa,Eliezer M. Van Allen,Eliezer M. Van Allen,Olivier Elemento,Olivier Elemento,Andrea Sboner,Andrea Sboner,Levi A. Garraway,Levi A. Garraway,Levi A. Garraway,Mark A. Rubin,Mark A. Rubin,Francesca Demichelis,Francesca Demichelis,Francesca Demichelis +28 more
TL;DR: Analysis of whole-exome sequencing data of metastatic biopsies from patients observed substantial genomic overlap between castration-resistant tumors that were histologically characterized as prostate adenocarcinomas and neuroendocrine prostate cancer (CRPC-NE), supporting the emergence of an alternative, 'AR-indifferent' cell state through divergent clonal evolution as a mechanism of treatment resistance in advanced prostate cancer.
Journal ArticleDOI
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher,Michael J. Morris,Walter M. Stadler,Celestia S. Higano,Ethan Basch,Karim Fizazi,Emmanuel S. Antonarakis,Tomasz M. Beer,Michael A. Carducci,Kim N. Chi,Paul G. Corn,Johann S. de Bono,Robert Dreicer,Daniel J. George,Elisabeth I. Heath,Maha Hussain,Wm. Kevin Kelly,Glenn Liu,Christopher J. Logothetis,David M. Nanus,Mark N. Stein,Dana E. Rathkopf,Susan F. Slovin,Charles J. Ryan,Oliver Sartor,Eric J. Small,Matthew R. Smith,Cora N. Sternberg,Mary-Ellen Taplin,George Wilding,Peter S. Nelson,Lawrence H. Schwartz,Susan Halabi,Philip W. Kantoff,Andrew J. Armstrong +34 more
TL;DR: The concept of no longer clinically benefiting is introduced to underscore the distinction between first evidence of progression and the clinical need to terminate or change treatment, and the importance of documenting progression in existing lesions as distinct from the development of new lesions.
Journal ArticleDOI
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Himisha Beltran,David S. Rickman,Kyung Park,Sung Suk Chae,Andrea Sboner,Theresa Y. MacDonald,Yuwei Wang,Karen Sheikh,Stéphane Terry,Scott T. Tagawa,Rajiv Dhir,Joel B. Nelson,Alexandre de la Taille,Yves Allory,Mark Gerstein,Sven Perner,Kenneth J. Pienta,Arul M. Chinnaiyan,Arul M. Chinnaiyan,Yuzhuo Wang,Colin Collins,Martin E. Gleave,Francesca Demichelis,Francesca Demichelis,David M. Nanus,Mark A. Rubin +25 more
TL;DR: There was dramatic and enhanced sensitivity of NEPC (and MYCN overexpressing PCA) to Aurora kinase inhibitor therapy both in vitro and in vivo, with complete suppression of neuroendocrine marker expression following treatment.